• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

    7/19/22 9:25:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPIX alert in real time by email

    NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors.

    Martin Brown Jr. joins Cumberland Pharmaceuticals' Board of Directors.

    Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. 

    Brown is an attorney at Adams and Reese LLP, a multi-disciplinary law firm with over 270 attorneys and advisors located throughout the United States. He has nearly 30 years of legal experience representing privately held businesses, counseling owners in complex business transactions, intellectual property licensing, international commerce, mergers and acquisitions, and estate planning. He has been listed since 2009 in the corporate law category of in Best Lawyers®.

    Additionally, he has served since 2018 on the board of directors of the parent company of Aegis Sciences Corporation, a federally certified health care laboratory headquartered in Nashville.

    Brown has been an active board member for many community organizations, including the Land Trust for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and Tennessee chapter of the Nature Conservancy.

    "Martin brings tremendous legal, health care and civic experience to Cumberland's Board of Directors," said A.J. Kazimi, Cumberland Pharmaceuticals CEO and Board Chairman. "We are honored to welcome him to our board and know his contributions will be valuable in supporting our mission to deliver innovative products that address poorly met medical needs."

    Brown earned his bachelor's degree from Yale University and his juris doctor from Vanderbilt University.

    Cumberland's Board of Directors also includes Kazimi; Dr. Gordon R. Bernard, executive vice president for research at Vanderbilt University Medical Center; Joey A. Jacobs, former Chairman and CEO of Acadia Healthcare; James R. Jones, former managing partner at KPMG; Caroline R. Young, former CEO of the Nashville Health Care Council and current vice president of partnership development at Frist Cressey Ventures; Kenneth J. Krogulski, managing partner and chief investment officer at Berkshire Asset Management; and Joseph C. Galante, a music industry executive and former Chairman of Sony Music Nashville and RCA Nashville.

    About Cumberland Pharmaceuticals

    Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology, rheumatology and oncology market segments. The company's portfolio includes eight FDA-approved brands.

    The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD), Systemic Sclerosis (SSc), and Aspirin-Exacerbated Respiratory Disease (AERD). More information can be found on the company's website at www.cumberlandpharma.com.

    Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-appoints-martin-brown-jr-to-its-board-of-directors-301588401.html

    SOURCE Cumberland Pharmaceuticals Inc.

    Get the next $CPIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline increased direct ownership by 0.27% to 33,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    10/3/25 4:03:06 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James increased direct ownership by 0.58% to 44,192 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    10/3/25 4:02:16 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J increased direct ownership by 0.00% to 5,700,284 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    10/3/25 4:01:46 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

     Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

    10/20/25 9:05:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle

    10/20/25 9:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

    Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Vibativ® in both the 12-vial carton and the newly introduced 4-vial Starter Pak. With expanded access, Premier membe

    10/13/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:36:28 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:35:26 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:34:18 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    SEC Filings

    View All

    Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    10/21/25 9:25:32 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cumberland Pharmaceuticals Inc.

    10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    8/8/25 5:03:12 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    8/5/25 5:05:48 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

    NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka.  Brown is an attorney at Adams and Reese LLP, a

    7/19/22 9:25:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Financials

    Live finance-specific insights

    View All

    CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

     Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

    10/20/25 9:05:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle

    10/20/25 9:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

    Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Vibativ® in both the 12-vial carton and the newly introduced 4-vial Starter Pak. With expanded access, Premier membe

    10/13/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/9/24 5:27:23 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/10/23 5:01:42 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/14/22 5:17:27 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care